Comparative Pharmacology
Head-to-head clinical analysis: ENDURONYL versus METAHYDRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDURONYL versus METAHYDRIN.
ENDURONYL vs METAHYDRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the Na+-Cl− symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption and promoting diuresis.
Metahydrin (trichlormethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing excretion of water, sodium, chloride, and potassium.
ENDURONYL (methyclothiazide and deserpidine) is a fixed-dose combination antihypertensive. Typical adult dose: 1 tablet (methyclothiazide 5 mg / deserpidine 0.25 mg) orally once daily. Dose may be increased to 2 tablets once daily if needed.
Oral, 50-100 mg once daily. Maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life 10-15 hours; clinically, may require 3-5 days to reach steady state in hypertension management.
18-30 hours (clinically relevant for once-daily dosing in hypertension; prolonged in renal impairment)
Primarily renal excretion; ~50% unchanged, ~25% as deserpidine metabolites, 20% biliary-fecal.
Renal: 30% (fecal: 70% as unabsorbed drug, primarily biliary elimination; <1% unchanged in urine)
Category C
Category C
Thiazide Diuretic + Rauwolfia Alkaloid
Thiazide Diuretic